ICCM IceCure Medical Ltd. - Ordinary Shares

NAS · US · Healthcare · Medical Devices · icecure-medical.com

1.570USD-7.10%Mkt Cap: 7.28M $P/E: —3d ago

IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, …

Industry Peers

Medical Devices

Screen all

ABT

Abbott Laboratories Common Stock

$169.83BUSDP/E 31.6

MDT

Medtronic plc. Ordinary Shares

$110.49BUSDP/E 21.2

SYK

Stryker Corporation Common Stock

$105.65BUSDP/E 28.5

BSX

Boston Scientific Corporation Common Stock

$61.74BUSDP/E 17.2

Edwards Lifesciences Corporation Common Stock

$49.03BUSDP/E 50.7

SHL

Siemens Healthineers AG

$46.06BUSDP/E 19.2

DXCM

DexCom, Inc. - Common Stock

$32.21BUSDP/E 33.7

GEHC

GE HealthCare Technologies Inc. - Common Stock

$29.24BUSDP/E 14.8

PHG

Koninklijke Philips N.V. NY Registry Shares

$23.38BUSDP/E 18.5

PHIA

Koninklijke Philips N.V.

$22.58BUSDP/E 18.5

STE

STERIS plc (Ireland) Ordinary Shares

Zimmer Biomet Holdings, Inc. Common Stock

$16.84BUSDP/E 21.4

PEN

Penumbra, Inc. Common Stock

$12.51BUSDP/E 77.8

TXG

10x Genomics, Inc. - Common Stock

$12.18BUSD

SNN

Smith & Nephew SNATS, Inc. Common Stock

$11.06BUSDP/E 18.0

GMED

Globus Medical, Inc. Class A Common Stock

Bio-Rad Laboratories, Inc. Class A Common Stock

$9.88BUSDP/E 45.0

GKOS

Glaukos Corporation Common Stock

$9.66BUSD

Key Statistics

Company

Market Cap7.28M USD

Enterprise Value-6.56M USD

Revenue (TTM)3.95M USD

Gross Profit1.23M USD

Net Income (TTM)-15.06M USD

Revenue/Share1.56 USD

Last Price1.570 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees67

CountryUS

SectorHealthcare

IndustryMedical Devices

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-0.48

PEG—

EV/EBITDA0.40

EV/Revenue-1.66

P/S1.85

P/B0.45

EPS (TTM)-6.84

EPS (Forward)-3.31

52W Range

1.5500% of range42.00

52W High42.00 USD

52W Low1.550 USD

Profitability

Gross Margin36.28%

Oper. Margin-487.76%

EBITDA Margin0.00%

Profit Margin-445.61%

ROE-166.36%

ROA-108.42%

Growth

Revenue Growth72.80%

Earnings Growth—

Cash Flow & Leverage

Operating CF-14.57M USD

CapEx (TTM)36.00K USD

FCF Margin-241.65%

FCF Yield-130.98%

Net Debt-11.94M USD

Net Debt/EBITDA0.73

Balance Sheet

Debt/Equity0.02

Current Ratio2.88

Quick Ratio2.15

Book Value/Sh3.47 USD

Cash/Share3.51 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Splits

Last Split1:30

Split DateJun 4, 2026

Analyst Consensus

Rating—

Target (Mean)22.67 USD

Upside (mean)+1343.7%

Target Range10.00 USD – 30.00 USD

10.00+1343.7% to mean30.00

# Analysts3

Ownership

Shares Out.4.64M

Float2.52M

Insiders51.49%

Institutions12.60%

Short Interest

Short Ratio0.6d

Short % Float2.92%

Short % Out.2.21%

Shares Short102.64K

Short (prev mo.)40.78K

Technical

SMA 502.405 (-34.7%)

SMA 2009.799 (-84.0%)

Beta0.45

S&P 52W Chg14.58%

Avg Vol (30d)162.84K

Avg Vol (10d)152.52K

Technical Indicators

RSI (14)25.3

MACD-0.2947

MACD Signal-0.3031

MACD Hist.+0.0084

BB Upper2.425 USD

BB Middle1.939 USD

BB Lower1.454 USD

BB Width50.10%

ATR (14)0.2051 USD

Vol Ratio (20d)2.70x